Literature DB >> 9561389

Single-dose cefodizime as infection prophylaxis in abdominal surgery: a prospective multicenter study.

F Thalhammer1, F Traunmüller, H J Böhming, D Depisch, W Ilias, U Hollenstein, G Salem, W Wayand, H Burgmann, S Breyer.   

Abstract

This prospective pilot study was performed to evaluate the efficacy, safety and tolerability of a single dose of cefodizime as infection prophylaxis in patients undergoing major abdominal surgery. One hundred forty-nine patients received 2g cefodizime, a third-generation cephalosporin, 30 min before abdominal surgery. The mean operation time was 116 +/- 66 min. Eighteen patients received metronidazole additionally. In 8/149 patients (5.4%) the final outcome was considered to be a treatment failure. 94.6% of the patients had no signs of infection. The long half-life of cefodizime allows a single-dose perioperative prophylaxis even in abdominal surgery lasting 3 to 4 h. Cefodizime can be regarded as a safe antibiotic prophylaxis with few side effects.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9561389     DOI: 10.1007/BF02767780

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  7 in total

1.  Single dose cefotaxime plus metronidazole versus three dose cefuroxime plus metronidazole as prophylaxis against wound infection in colorectal surgery: multicentre prospective randomised study.

Authors:  D C Rowe-Jones; A L Peel; R D Kingston; J F Shaw; C Teasdale; D S Cole
Journal:  BMJ       Date:  1990-01-06

Review 2.  Immunomodulating effects of antibiotics: literature review.

Authors:  B Van Vlem; R Vanholder; P De Paepe; D Vogelaers; S Ringoir
Journal:  Infection       Date:  1996 Jul-Aug       Impact factor: 3.553

Review 3.  Antibiotics in surgery. An overview.

Authors:  D E Fry
Journal:  Am J Surg       Date:  1988-05-31       Impact factor: 2.565

4.  Prospective randomized comparison of cefodizime versus cefuroxime for perioperative prophylaxis in patients undergoing coronary artery bypass grafting.

Authors:  C Wenisch; A Bartunek; K Zedtwitz-Liebenstein; M Hiesmayr; B Parschalk; T Pernerstorfer; W Graninger
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

Review 5.  Prophylaxis of postoperative infections.

Authors:  D H Wittmann; R E Condon
Journal:  Infection       Date:  1991       Impact factor: 3.553

Review 6.  Cefodizime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  L B Barradell; R N Brogden
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

7.  Dose linearity and other pharmacokinetics of cefodizime after single-dose intravenous administration.

Authors:  E E Dagrosa; P Hajdú; V Malerczyk; S de Looze; K Seeger; H Grötsch
Journal:  Clin Ther       Date:  1987       Impact factor: 3.393

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.